Related references
Note: Only part of the references are listed.CTLA-4: Negative regulator of the immune response and a target for cancer therapy
Ulrich Keilholz
JOURNAL OF IMMUNOTHERAPY (2008)
The role of the CTLA4 blockade in the treatment of malignant melanoma
Lee D. Cranmer et al.
CANCER INVESTIGATION (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
The spectrum and significance of primary hypophysitis
CC Cheung et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Share Paper
